Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Features that define clinical severity of ulcerative pyoderma gangrenosum: a Delphi consensus study of experts and patients on behalf of the US Medical Dermatology Society.
Journal: The British journal of dermatology
Published: December 17, 2022
Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis.
Journal: The Journal of rheumatology
Published: October 01, 2015
A Highly Sensitive and Drug-Tolerant Anti-Drug Antibody Screening Assay for Ixekizumab using Affinity Capture Elution.
Journal: The Journal of investigative dermatology
Published: August 18, 2015
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Journal: Lancet (London, England)
Published: June 15, 2015
A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: March 17, 2015
Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: September 25, 2014
Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: July 17, 2014
IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood.
Journal: The Journal of investigative dermatology
Published: July 08, 2014
A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
Journal: Journal of the American Academy of Dermatology
Published: May 29, 2014
Showing 1-10 of 10
Last Updated: 09/26/2026